NCT05787574 - A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions

Primary Immune Regulatory DisorderAutoimmune LymphoproliferativeImmune System Diseases

Interventions

DRUG

Emapalumab

Emapalumab on Days -22 (22 days before the day of the stem cell transplant), -15, -8, and -1.

DRUG

Fludarabine and Dexamethasone

Fludarabine and dexamethasone for 5 days in a row on Days -22 through -18.

PROCEDURE

Stem Cell Transplant

Participants in both groups will receive their standard-of-care stem cell transplant on Day 0.

Trial Locations (12)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack

19104

RECRUITING

Children's Hospital of Philadelphia (Data Collection Only), Philadelphia

30322

RECRUITING

Children's Healthcare of Atlanta (Data Collection Only), Atlanta

53226

RECRUITING

Children's Hospital of Wisconsin (Data Collection Only), Milwaukee

77030

RECRUITING

Texas Children's Hospital (Data Collection), Houston

94143

RECRUITING

University of California, San Francisco (Data collection only), San Francisco

07920

RECRUITING

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors

collaborator

Sobi, Inc.

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER